Understanding a Cell's 'Doorbell': Drug Design Advances are the Research Goal
News Apr 13, 2018 | Original story from DOE/LOS Alamos National Laboratory
A multi-institutional project to understand one of the major targets of human drug design has produced new insights into how structural communication works in a cell component called a G protein-coupled receptor (GPCRs), basically a "doorbell" structure that alerts the cell of important molecules nearby. Understanding the structure and function of the receptor more deeply will enable better drug development.
"It's a huge field of active research in academia and industry because if we can figure out precisely how GPCRs work, then we can more easily design drugs to change their behavior and thereby control pain, hunger, and more," said coauthor Christopher Neale, a researcher with the Center for Nonlinear Studies at Los Alamos National Laboratory. "This work helps us in understanding the receptors' function as a means to enable future drug discovery. For instance, if calcium binding can turn off a GPCR, then one may use that knowledge in a guided search for drugs that either promote or inhibit calcium binding depending on the desired health outcome."
GPCRs are a family of membrane proteins that transmit information into our cells. They respond to things like adrenaline and opioid drugs, and they are the largest class of human drug targets. The research reported this week in Nature Communications describes the regulation of GPCRs by physiological ions such as sodium, calcium and magnesium.
This article has been republished from materials provided by DOE/LOS Alamos National Laboratory. Note: material may have been edited for length and content. For further information, please contact the cited source.
Protein Target Identified That Could Prevent StrokesNews
Scientists have identified a protein, called GPR68, that senses blood flow and tells small blood vessels called arterioles when to dilate. The researchers believe medications that activate GPR68 could one day be useful to treat medical conditions, including ischemic stroke.READ MORE
Neuropeptide Y Y1 Receptor Structure Solved, Offers New Opportunities for Anti-obesity Drug DiscoveryNews
Scientists solve the crystal structure of Neuropeptide Y Y1 Receptor, offering new opportunities for anti-obesity drug discovery.READ MORE
Crystal Structure of Neuropeptide 1 Receptor Solved, Providing Therapeutic Angle For Obesity TreatmentNews
An international team has uncovered the potential to beat obesity at the cellular level, characterizing for the first time a complex, little-understood receptor type that, when activated, shuts off hunger.READ MORE